New drug combo targets metastatic tumors in early safety trial

NCT ID NCT05678010

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether a new drug called AZD1390 is safe when given together with a precise type of radiation therapy (SBRT) for people whose solid tumors have spread to other parts of the body. The study involves 54 adults with metastatic cancer. The main goal is to check for side effects and find the best dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma metastatic malignant neoplasm metastatic neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CANCER METASTATIC SOLID TUMOR METASTATIC TUMOR SOLID CARCINOMA SOLID TUMOR SOLID TUMOR, ADULT

Contacts and locations

Show contact details

Locations

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)

Harrison, New York, 10604, United States
University of Washington (Data Collection AND Data Analysis)

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.